Outcomes of Patients With Nasopharyngeal Plasmacytoma: A Systematic Review

Omar Ramadan*

Outcomes of Patients With Nasopharyngeal Plasmacytoma: A Systematic Review.

This study reviews the published literature related to
nasopharyngeal plasmacytoma. Clinical
presentation, demographics, treatment,
and outcomes of this uncommon disease
have been reported.

A systematic review of studies on
nasopharyngeal plasmacytoma from 1935 to 2016
was conducted. A PubMed database search was performed
for articles related to this condition
along with the bibliographies of those selected articles.
Articles were examined for patient data
that reported the disease outcome.

Fifty-eight journal articles were included
in this analysis, comprising of a total of 114
studies indicative of a predilection for cases particularly in
men with a mean age of 55 years
characterized with symptoms such as nasal obstruction, epistaxis and
neck lymphadenopathy.

Radiotherapy was the most common treatment modality, followed by
a combination of surgery and radiotherapy.

Of the 3 most common treatment modalities, a
combination of radiotherapy and surgery
had the most favorable outcome for a majority of patients.
The existing condition for
8 patients (7%) deteriorated leading to the development
of multiple myeloma.

This review contains a large pool of
information about nasopharyngeal
plasmacytoma patients examined to date suggesting
that aggressive radiotherapy is the most common
treatment modality for this condition.

Extramedullary plasmacytoma is an uncommon tumor,
constituting only 3% of all
plasma cell neoplasms and less
than 1% of all head and neck tumors.

Thus, there is little evidence regarding the epidemiology,
optimal management, and long-term prognosis for these
types of cancers.

Therefore, in this
article; we perform a systematic review of 114
cases of nasopharyngeal EMPs, representing the
largest unified collection of nasopharyngeal EMPs investigated to date.

Our goal was to analyze the demographics, presentation symptoms, treatment modalities,
prognosis, recurrence, and microcystic meningioma development of this rare form
of tumor.

Otolaryngol Open J. 2017; 3(2): 30-40. doi: 10.17140/OTLOJ-3-139